Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antidepressant |
| gptkbp:approvalYear |
2019
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:N06AX27
|
| gptkbp:brand |
gptkb:Zulresso
|
| gptkbp:CASNumber |
99614-02-5
|
| gptkbp:chemicalClass |
neurosteroid
|
| gptkbp:developedBy |
gptkb:Sage_Therapeutics
|
| gptkbp:hasMolecularFormula |
C21H34O2
|
| https://www.w3.org/2000/01/rdf-schema#label |
brexanolone
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
positive allosteric modulator of GABA-A receptor
|
| gptkbp:pregnancyCategory |
unknown
|
| gptkbp:relatedTo |
gptkb:allopregnanolone
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
loss of consciousness
sedation dry mouth flushing |
| gptkbp:usedFor |
postpartum depression
|
| gptkbp:bfsParent |
gptkb:Zulresso
|
| gptkbp:bfsLayer |
6
|